Current Report Filing (8-k)
14 November 2022 - 10:32PM
Edgar (US Regulatory)
false 0000949858 0000949858 2022-11-14
2022-11-14
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 14,
2022
ACHIEVE LIFE SCIENCES, INC.
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
|
Delaware
|
|
033-80623
|
|
95-4343413
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
1040 West Georgia, Suite 1030
Vancouver, BC, Canada
|
|
V6E 4H1
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant’s Telephone Number, Including Area Code: (604)
210-2217
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions (see General
Instruction A.2. below):
|
|
☐
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
Title of each
class
|
Trading Symbol
|
Name of exchange on which
registered
|
Common Stock, par value $0.001 per share
|
ACHV
|
The NASDAQ Capital Market
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 2.02 Results of Operations and
Financial Condition.
On November 14, 2022, Achieve Life Sciences, Inc. issued a press
release announcing its financial results for the third quarter
ended September 30, 2022. A copy of the press release is furnished
as Exhibit 99.1 to this Current Report on Form
8-K.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
________________________
The information in Item 2.02 of this Form 8-K and Exhibit 99.1
attached hereto is furnished and shall not be deemed “filed” for
purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”), nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933, as
amended, or the Exchange Act, except as shall be expressly set
forth by specific reference in such filing.
________________________
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized.
|
|
|
ACHIEVE LIFE SCIENCES, INC.
|
Date: November 14, 2022
|
/s/ John Bencich
|
|
John Bencich
Chief Executive Officer (Principal Executive and Financial
Officer)
|
Achieve Life Sciences (NASDAQ:ACHV)
Historical Stock Chart
Von Jan 2023 bis Feb 2023
Achieve Life Sciences (NASDAQ:ACHV)
Historical Stock Chart
Von Feb 2022 bis Feb 2023